Pompe Disease (GSD II) Clinical Trials and Treatments

Pompe disease is an autosomal recessive lysosomal storage disorder caused by deficiency of acid alpha-glucosidase (GAA), an enzyme essential for breaking down glycogen. Without adequate enzyme activity, glycogen accumulates excessively in lysosomes throughout the body, with most severe impact on skeletal muscle, cardiac muscle, and the diaphragm. The infantile-onset form (before age 12 months) is the most severe, characterized by hypotonia, feeding difficulties, and progressive cardiomyopathy that can be fatal by age 2 without treatment.

The most common symptoms of Pompe Disease include Progressive muscle weakness and loss of tone, Heart enlargement (cardiomegaly) in infants, Breathing difficulties, especially when lying flat, Hypotonia and feeding difficulties in infants, Exercise intolerance and fatigue in older children, among others. Pompe Disease affects approximately 1 in 40,000 people (infantile form: 1 in 138,500; late-onset: 1 in 60,000). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Pompe Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Pompe disease treatment outcomes have improved dramatically since enzyme replacement became available, and research continues to push boundaries. Clinical trials are testing gene therapies, Shionogi's oral S-606001 added to enzyme replacement, Denali's engineered enzyme DNL952 and less frequent enzyme dosing.

Yes. As of October 21, 2026, 3 FDA-approved medicines have a current label that names Pompe Disease: Lumizyme (alglucosidase alfa), first approved in 2006; Nexviazyme (avalglucosidase alfa), first approved in 2021; and Pombiliti + Opfolda (cipaglucosidase alfa + miglustat), first approved in 2023. Corticosteroids and immune globulins count once each.

Pompe Disease is caused by variants in the GAA gene. All forms, infantile and late-onset, are caused by biallelic GAA variants; enzyme assay plus GAA sequencing confirms.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. The condition affects approximately 1 in 40,000 people (infantile form: 1 in 138,500; late-onset: 1 in 60,000). Genetic testing confirms the diagnosis.

Yes. Genetic testing for Pompe Disease looks at the GAA gene. All forms, infantile and late-onset, are caused by biallelic GAA variants; enzyme assay plus GAA sequencing confirms.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Pompe Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Pompe Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.